文献速递类风湿关节炎

类风湿关节炎患者起始甲氨蝶呤或生物制剂治疗时工作出勤、缺勤及失业的预测因素

Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

研究基于英国两个前瞻性队列,纳入全职或兼职工作的类风湿关节炎患者,分别起始甲氨蝶呤或生物制剂治疗,随访1年。结果显示心理困扰和残疾分别预测甲氨蝶呤和生物制剂队列的工作丢失,残疾预测缺勤,疲劳和残疾分别预测两个队列的出勤主义,良好的EULAR反应与较低缺勤和出勤主义相关。

要点

  • 心理困扰预测甲氨蝶呤起始者工作丢失,残疾预测生物制剂起始者工作丢失。
  • 残疾预测缺勤,疲劳和残疾分别预测甲氨蝶呤和生物制剂起始者的出勤主义。
  • 良好的EULAR反应与两个队列较低的缺勤和出勤主义相关。

核心结论

  • 类风湿关节炎患者在工作能力方面仍面临显著限制。
  • 残疾和EULAR反应是工作结局的主要预测因素,强调控制疾病和维持功能对工作参与的重要性。

研究设计与样本

  • 研究纳入英国两个前瞻性队列中年龄18-65岁、全职或兼职工作的类风湿关节炎患者:甲氨蝶呤起始者来自Rheumatoid Arthritis Medication Study,生物制剂起始者来自Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate。
  • 使用RA特异性工作生产力调查在基线、6个月和12个月评估出勤主义和缺勤,并分析基线年龄、性别、临床指标(如残疾、疼痛、疲劳)、心理困扰、职业及基线至6个月的EULAR反应等潜在预测因素。

主要发现

  • 12个月内,甲氨蝶呤起始者51/463人、生物制剂起始者30/260人离开工作。
  • 甲氨蝶呤起始者基线心理困扰较高[OR 1.1(95%CI:1.0,1.1)]和生物制剂起始者残疾较高[OR 3.5(95%CI:1.4,8.6)]预测工作丢失。
  • 16.1%的患者报告病假,残疾预测病假[OR(95%CI):甲氨蝶呤起始者1.5(0.9,2.3);生物制剂起始者2.4(1.1,5.2)]。
  • 两个队列的出勤主义评分中位数非常低(极小干扰);甲氨蝶呤起始者疲劳较高[发生率比1.2(95%CI:1.0,1.4)]和生物制剂起始者残疾较高[发生率比1.4(95%CI:1.1,1.7)]预测出勤主义。
  • 两个队列中良好的EULAR反应与较低的缺勤和出勤主义相关。

临床怎么用

  • 对于起始甲氨蝶呤或生物制剂治疗的类风湿关节炎患者,应关注心理困扰、残疾和疲劳等可干预因素以改善工作结局。
  • 控制疾病活动达到良好EULAR反应可能有助于减少缺勤和出勤主义。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Work is an important health outcome. This study aimed to identify predictors of work loss, absenteeism and presenteeism over 1 year in RA patients commencing treatment with MTX or biologics. METHODS: Patients aged 18-65 years in full/part-time employment from two UK prospective cohorts were included: MTX-starters = Rheumatoid Arthritis Medication Study; and biologic-starters = Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate. Presenteeism and absenteeism were assessed using the RA-specific Work Productivity Survey at baseline, and 6 and 12 months. Potential predictors including baseline age, gender, clinical measures (e.g. disability, pain, fatigue), psychological distress, occupation and EULAR response from baseline to 6 months were investigated. RESULTS: A total of 51/463 MTX-starters and 30/260 biologic-starters left work over 12 months. Higher baseline psychological distress in MTX-starters [odds ratio (OR) 1.1 (95% CI: 1.0, 1.1)] and higher disability in biologic-starters [OR 3.5 (95% CI: 1.4, 8.6)] predicted work loss. Some 16.1% of patients reported sick-leave, which was predicted by disability [OR (95% CI): MTX-starters: 1.5 (0.9, 2.3); biologic-starters: 2.4 (1.1, 5.2)]. Median presenteeism scores were very low (minimal interference) in both cohorts. Higher fatigue for MTX starters [incidence rate ratio 1.2 (95% CI: 1.0, 1.4)] and higher disability in biologic-starters (incidence rate ratio 1.4 (95% CI: 1.1, 1.7)] predicted presenteeism. Good EULAR response was associated with lower absenteeism and presenteeism in both cohorts. CONCLUSION: Patients with RA still face significant limitations regarding their ability to work. Disability and EULAR response were the main predictors of work outcomes, emphasizing the need to control the disease and the importance of function in enabling work participation.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Gwinnutt JM, Leggett S, Lunt M, et al. Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis. Rheumatology (Oxford). 2020. PMID: 32097471. doi:10.1093/rheumatology/keaa027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。